Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances

References

• Fiddler C, Parfrey H. Diffuse parenchymal lung disease. Medicine. 2023;51(12):829–837. doi: 10.1016/j.mpmed.2023.09.007
   Google Scholar
• Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. doi: 10.1183/16000617.0100-2018
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748. doi: 10.1164/rccm.201308-1483ST
   PubMed Web of Science ®Google Scholar
• Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res. 2009;2:1–11.
   PubMedGoogle Scholar
• Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Resp J. 2013;41(5):1207–1218. doi: 10.1183/09031936.00073012
   PubMed Web of Science ®Google Scholar
• Kaul B, Cottin V, Collard HR, et al. Variability in global prevalence of interstitial lung disease. Front Med. 2021;8:751181. doi: 10.3389/FMED.2021.751181
   Google Scholar
• Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Resp J. 2023;61(3). doi: 10.1183/13993003.03187-2021
   PubMedGoogle Scholar
• De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8(1):1. doi: 10.3390/JCM8010014
   PubMedGoogle Scholar
• Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir med. 2013;107(8):247–1252. doi: 10.1016/J.RMED.2013.05.002
   Google Scholar
• Kreuter M, Wälscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med. 2017;23(5):418–425. doi: 10.1097/MCP.0000000000000408
   PubMedGoogle Scholar
• Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:150. doi: 10.1183/16000617.0076-2018
   Google Scholar
• Harari S. Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease. Eur Respir Rev. 2018;27(150):150. doi: 10.1183/16000617.0110-2018
   Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what’s in a name? Eur Resp J. 2019;53(2):1801939. doi: 10.1183/13993003.01939-2018
   PubMedGoogle Scholar
• Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4:e000212. doi: 10.1136/bmjresp-2017-000212
   PubMed Web of Science ®Google Scholar
• Simpson T, Barratt SL, Beirne P, et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Resp J. 2021;58(1):2100221. doi: 10.1183/13993003.00221-2021
   PubMedGoogle Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):E18–E47. doi: 10.1164/RCCM.202202-0399ST
   PubMed Web of Science ®Google Scholar
• Cottin V, Teague R, Nicholson L, et al. The burden of progressive-fibrosing interstitial lung diseases. Front Med. 2022;9:799912. doi: 10.3389/fmed.2022.799912
   Web of Science ®Google Scholar
• Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021 Feb 11;57(2):2002718. Faverio P et al. Respiration. 2020;99(10):838-845. doi: 10.1183/13993003.02718-2020
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Opin Pulm Med. 2019;35(11):11,2015–2024. doi: 10.1080/03007995.2019.1647040
   Google Scholar
• Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Resp J. 2022;60(4):4. doi: 10.1183/13993003.02571-2021
   Google Scholar
• Nasser M, Larrieu S, Boussel L, et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res. 2021;22(1):162. doi: 10.1186/s12931-021-01749-1
   PubMedGoogle Scholar
• Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther. 2021;38(2):854–867. doi: 10.1007/s12325-020-01578-6
   PubMed Web of Science ®Google Scholar
• Pugashetti JV, Adegunsoye A, Wu Z, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med. 2023;207(1):69–76. doi: 10.1164/rccm.202201-0124OC
   PubMedGoogle Scholar
• du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382–1389. doi: 10.1164/rccm.201105-0840OC
   PubMed Web of Science ®Google Scholar
• George PM, Spagnolo P, Kreuter M, et al. Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925–934. doi: 10.1016/S2213-2600(20)30355-6
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi: 10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692. doi: 10.1183/13993003.00692-2018
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis–associated interstitial lung disease. Arthritis Rheumatol. 2017;69(3):542–549. doi: 10.1002/art.39971
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328. doi: 10.1183/09031936.00092309
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69(3):216–222. doi: 10.1136/thoraxjnl-2013-203843
   PubMed Web of Science ®Google Scholar
• Messina R, Guggino G, Benfante A, et al. Interstitial lung disease in elderly rheumatoid arthritis patients. Drugs Aging. 2020;37(1):11–18. doi: 10.1007/s40266-019-00727-Z
   PubMed Web of Science ®Google Scholar
• Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow’s ear. Thorax. 2013;68(4):309–310. doi: 10.1136/thoraxjnl-2012-202640
   PubMedGoogle Scholar
• Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202(3):e36–e69. doi: 10.1164/rccm.202005-2032ST
   PubMed Web of Science ®Google Scholar
• Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24(135):1–16. doi: 10.1183/09059 180.00008014.
   PubMedGoogle Scholar
• Khan T, Jose RJ, Renzoni EA, et al. A closer look at the role of anti-CCP antibodies in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and bronchiectasis. Rheumatol Ther. 2021;8(4):1463–1475. doi: 10.1007/s40744-021-00362-4
   PubMedGoogle Scholar
• Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55(5):1902026. doi: 10.1183/13993003.02026-2019
   PubMed Web of Science ®Google Scholar
• Volkmann ER. Natural history of systemic sclerosis–related interstitial lung disease: how to identify a progressive fibrosing phenotype. J Scleroderma Relat Disord. 2020;5(Suppl):31–40. doi: 10.1177/2397198319889549
   PubMedGoogle Scholar
• Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146(2):422–436. doi: 10.1378/chest.13-2626
   PubMed Web of Science ®Google Scholar
• Strehl C, Spies CM, Buttgereit F. Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011;29(5 Suppl 68):SS13–S8.
   Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640–646. doi: 10.3899/jrheum.121043
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118. doi: 10.1016/s0162-3109(00)00188-0
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30–36. doi: 10.1378/chest.130.1.30
   PubMed Web of Science ®Google Scholar
• Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–1124. doi: 10.1172/JCI18384
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719. doi: 10.1016/S2213-2600(16)30152-7
   PubMed Web of Science ®Google Scholar
• Clements PJ, Roth MD, Elashoff R, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007;66(12):1641–1647. doi: 10.1136/ard.2007.069518
   PubMedGoogle Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi: 10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–123. doi: 10.1053/j.seminhematol.2010.01.011
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European scleroderma trial and research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–1194. doi: 10.1136/annrheumdis-2013-204522
   PubMed Web of Science ®Google Scholar
• Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106–2113. doi: 10.1093/rheumatology/key213
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, Te K Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314–324. doi: 10.1164/rccm.201203-0513CI
   PubMed Web of Science ®Google Scholar
• Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151(3):619–625. doi: 10.1016/j.chest.2016.10.029
   PubMed Web of Science ®Google Scholar
• Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74(4):443–450. doi: 10.1007/s40265-014-0190-z
   PubMed Web of Science ®Google Scholar
• Song JW, Lee H-K, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):103–112.
   PubMedGoogle Scholar
• Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018;23(11):1041–1048. doi: 10.1111/resp.13365
   PubMed Web of Science ®Google Scholar
• Li L, Liu R, Zhang Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2020;39(5):1457–1470. doi: 10.1007/s10067-019-04846-1
   PubMed Web of Science ®Google Scholar
• Kelly C, Palmer E, Gordon J, et al. OP0037 Pulsed cyclophosphamide in the treatment of rheumatoid arthritis-related interstitial lung disease (RA-ILD). Ann Rheum Dis. 2014;73(Suppl. 2):74.1–74. doi: 10.1136/annrheumdis-2014-eular.2342
   Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337(5):329–335. doi: 10.1097/MAJ.0b013e31818d094b
   PubMed Web of Science ®Google Scholar
• Barnes H, Holland AE, Westall GP, et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. 2018;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2
   PubMedGoogle Scholar
• Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford). 2021;60(4):1882–1890. doi: 10.1093/rheumatology/keaa577
   PubMedGoogle Scholar
• Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. doi: 10.1183/13993003.02071-2022
   PubMed Web of Science ®Google Scholar
• Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45–54. doi: 10.1016/S2213-2600(22)00359-9
   PubMed Web of Science ®Google Scholar
• Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on sarcoidosis. Thorax. 2020;(1):4–20. doi: 10.1136/thoraxjnl-2019-214348
   PubMedGoogle Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–66.
   PubMed Web of Science ®Google Scholar
• Hamzeh N, Voelker A, Forssén A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir med. 2014;108(11):1663–1669. doi: 10.1016/j.rmed.2014.09.013
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812. doi: 10.1378/chest.12-1728
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150. doi: 10.1183/09031936.00195010
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802. doi: 10.1164/rccm.200603-402OC
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, Te K Jr, et al. Idiopathic pulmonary fibrosis clinical research network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–1977. doi: 10.1056/NEJMoa1113354
   PubMed Web of Science ®Google Scholar
• Zhang D, Adegunsoye A, Oldham JM, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023;62(5):2300441. doi: 10.1183/13993003.00441-2023
   PubMedGoogle Scholar
• Pleasants R, Tighe RM. Management of idiopathic pulmonary fibrosis. Ann Pharmacother. 2019;53(12):1238–1248. doi: 10.1177/1060028019862497
   PubMed Web of Science ®Google Scholar
• Glassberg MK. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. Am J Manag Care. 2019;25(11 Suppl):S195–S203.
   PubMedGoogle Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi: 10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253. doi: 10.1183/13993003.00026-2015
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(3):147–157. doi: 10.1016/S2213-2600(19)30341-8
   PubMedGoogle Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476–486. doi: 10.1016/S2213-2600(20)30554-3
   PubMed Web of Science ®Google Scholar
• Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87–96. doi: 10.1016/S2213-2600(22)00260-0
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. doi: 10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Dixon G, Hague S, Mulholland S, et al. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Res. 2024;10(1):00529–2023. doi: 10.1183/23120541.00529-2023
   PubMedGoogle Scholar
• Brighton LJ, Miller S, Farquhar M, et al. Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. Thorax. 2019;74(3):270–281. doi: 10.1136/thoraxjnl-2018-211589
   PubMed Web of Science ®Google Scholar
• Barnes-Harris M, Allgar V, Booth S, et al. Battery-operated fan and chronic breathlessness: does it help? BMJ Support Palliat Care. 2019;9(4):478–481. doi: 10.1136/bmjspcare-2018-001749
   PubMed Web of Science ®Google Scholar
• van Manen MJ, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–286. doi: 10.1183/16000617.0090-2015
   PubMed Web of Science ®Google Scholar
• Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024;12(4):273–280. doi: 10.1016/S2213-2600(23)00432-0
   PubMed Web of Science ®Google Scholar
• Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390–1413. doi: 10.1164/rccm.200508-1211ST
   PubMed Web of Science ®Google Scholar
• Khor YH, Gutman L, Abu Hussein N, et al. Incidence and prognostic significance of hypoxemia in fibrotic interstitial lung disease: an international cohort study. Chest. 2021;160(3):994–1005. doi: 10.1016/j.chest.2021.04.037
   PubMedGoogle Scholar
• Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir med. 2005;99(4):408–414. doi: 10.1016/j.rmed.2004.09.005
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803–809. doi: 10.1164/rccm.200604-488OC
   PubMed Web of Science ®Google Scholar
• Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–1394. doi: 10.1164/rccm.201101-0138OC
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–376. doi: 10.1016/S2213-2600(13)70105-X
   PubMed Web of Science ®Google Scholar
• Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–752. doi: 10.1378/chest.129.3.746
   PubMed Web of Science ®Google Scholar
• Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007;131(3):650–656. doi: 10.1378/chest.06-1466
   PubMedGoogle Scholar
• Patel NM, Lederer DJ, Borczuk AC, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132(3):998–1006. doi: 10.1378/chest.06-3087
   PubMedGoogle Scholar
• Krishnan V, McCormack MC, Mathai SC, et al. Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest. 2008;134(4):693–698. doi: 10.1378/chest.08-0173
   PubMed Web of Science ®Google Scholar
• Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136(3):772–778. doi: 10.1378/chest.08-2776
   PubMed Web of Science ®Google Scholar
• Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung. 2007;185(3):173–178. doi: 10.1007/s00408-007-9004-3
   PubMed Web of Science ®Google Scholar
• Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir med. 2010;104(7):1035–1041. doi: 10.1016/j.rmed.2010.02.008
   PubMed Web of Science ®Google Scholar
• Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164(5):551–556. doi: 10.1001/archinte.164.5.551
   PubMedGoogle Scholar
• Kreuter M, Ehlers-Tenenbaum S, Schaaf M, et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015;31(4):266–274.
   PubMed Web of Science ®Google Scholar
• Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157–164. doi: 10.1378/chest.14-0359
   PubMed Web of Science ®Google Scholar
• Kilpeläinen M, Hirvonen T, Perkonoja K, et al. Clinical characteristics and disease course of fibrosing interstitial lung disease patients in a real-world setting. Medicina (Kaunas). 2023 31;59(2):281. doi: 10.3390/medicina59020281
   PubMedGoogle Scholar
• Richeldi L, Azuma A, Cottin V, et al. Trial of a preferential phosphodiesterase 4b inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386(23):2178–2187. doi: 10.1056/NEJMoa2201737
   PubMed Web of Science ®Google Scholar
• Maher TM, Assassi S, Azuma A, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Resp Res. 2023;10(1):1580. doi: 10.1136/bmjresp-2022-001580
   Google Scholar
• Corte T, Behr J, Cottin V, et al. RCT Abstract- BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial. Eur Resp J. 2023;62: RCT800. doi: 10.1183/13993003.congress-2023.RCT800
   Google Scholar
• West A, Chaudhuri N, Barczyk, et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial. Thorax. 2023;78(9):882–889. doi: 10.1136/thorax-2022-219391
   PubMedGoogle Scholar
• Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021;9(11):1266–1274. doi: 10.1016/S2213-2600(21)00165-X
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334. doi: 10.1056/NEJMoa2008470
   PubMed Web of Science ®Google Scholar
• Kulkarni T, Kawano-Dourado L, Johannson K, et al. A randomised, embedded, multifactorial adaptive platform trial for ILD (REMAP-ILD): The conceptual design. Eur Resp J. 2023;62: OA 2588. doi: 10.1183/13993003.congress-2023.OA2588
   Google Scholar
• Jun JI, Lau LF. Resolution of organ fibrosis. J Clin Invest. 2018;128(1):97–107. doi: 10.1172/JCI93563
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kaner RJ, Guiot J, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158(2):646–659. doi: 10.1016/j.chest.2020.03.037
   PubMed Web of Science ®Google Scholar